> > Educational Materials

Education for your patients.

Novo Nordisk helps you support your patients with resources and tools for success, right from the start. Educational materials available to download or have delivered to your office.

  • Patient Brochure

    This brochure describes key attributes of Novoeight®, with additional information on patient support and product support.

    Download

    Add to Order

  • Reconstitution Video

    This patient-friendly educational tool shows both patients and HCPs how to correctly prepare Novoeight® for infusion.

    Watch Video

  • Conversation Starter

    This 2-sided, 4-panel print piece is designed to help patients evaluate their treatment needs and show them how Novoeight® can meet those needs.

    Download

    Add to Order

  • Small Kit

    Novoeight® is ready to go when they are. This stylish and customizable kit makes it easy to take up to a week’s worth of treatment on the go.

    Get a Kit

  • Demonstration Kit

    This kit demonstrates the compact storage size and portability of Novoeight®, and helps you show patients how quick it is to reconstitute a dose of Novoeight®. Patients may practice mixing a dose to become familiar with the process before leaving your office. Please see full Prescribing Information for complete Instructions for Use.

    Get a Kit

  • Novoeight® is Ready To Go

    Team Novo8™ member Vaughn chooses Novoeight® because its portability features support his active lifestyle. Share his story with patients looking for treatment options designed to fit their daily lives.

    Watch Video

  • Hemophilia Dictionary

    This handy reference defines common terms used when talking about various bleeding disorders, with statistics and other facts that may help increase your patients’ understanding and awareness.

    Download

    Add to Order

Education for you.

Let us help you educate your patients with bleeding disorders, through our comprehensive selection of professional educational materials.

View Materials

View Materials

Patient advocacy groups.

Also available from Novo Nordisk:

NovoSeven® RT Logo

Visit website  | Prescribing Information

Esperoct® Logo

Visit website | Prescribing Information

Tretten® Logo

Visit website | Prescribing Information

Rebinyn® Logo

Visit website  | Prescribing Information

Selected Important Safety Information

Contraindications

  • Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins

Warnings and Precautions

  • Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment

Indications and Usage

Novoeight® (antihemophilic factor, recombinant) is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management, and routine prophylaxis to reduce the frequency of bleeding episodes.

  • Novoeight® is not indicated for the treatment of von Willebrand disease

Important Safety Information

Contraindications

  • Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins

Warnings and Precautions

  • Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment
  • Development of activity-neutralizing antibodies (inhibitors) may occur. Previously untreated patients (PUPs) are at greatest risk for inhibitor development with all factor VIII products. Inhibitors have been reported following administration of Novoeight in PUPs. If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform testing for factor VIII inhibitors

Adverse Reactions

  • The most frequently reported adverse reactions (≥1%) were inhibitors in Previously Untreated Patients (PUPs), injection site reactions, and pyrexia.

Please click here for Prescribing Information